InMed Pharmaceuticals develops small molecule drug candidates for Alzheimer's, eye disease and a skin condition. It last closed at $14.70 on Nov 20, down 3.57% on the day. For the quarter ended Sep 2026, MTRI reported EPS of -$0.42. Over the last 12 months MTRI insiders bought $1.4M of stock on the open market and sold $0, according to SEC Form 4 filings.
AI Auto Pilots
Is MTRI in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold MTRI.
StreetAlpha's call on MTRIStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
SampleMade up numbers, showing what this section looks like for MTRI. AI Starter and AI Pro members see the real figures.Sign up freeSign in
Pullback inside a longer uptrend, nearing oversold
The stock is 8% below its 20 day and 6% below its 50 day average. It is 12% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 37), near oversold. The nearest support is the Pivot S1 at $98.20, and the nearest resistance the Pivot at $102.10.
Short trendBearish
Long trendBullish
MomentumFading
StretchNear oversold
VolatilityNormal, 3.1%/day
Key levels
$121.5052 week high+21.5%
$108.7020 day average+8.7%
$106.4050 day average+6.4%
$103.90Pivot R1+3.9%
$102.10Pivot+2.1%
$100.00Last close
$98.20Pivot S1−1.8%
$96.40Swing low−3.6%
$89.30200 day average−10.7%
$71.2052 week low−28.8%
Indicators
RSI (14)
37.20
Weak, oversold below 30
Neutral
MACD
-1.84
Below its signal line
Bearish
Stochastic
24.5
Middle of its range
Neutral
ADX (14)
21.4
Weak trend
Williams %R
-82.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-121.3
Oversold below −100, overbought above 100
Oversold
Rate of change
−6.2%
Change over 10 sessions
Bearish
ATR (14)
$3.10
Typical daily range, 3.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for MTRI
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how MTRI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for MTRIHow many large options trades hit MTRI, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in MTRI in the last 90 days.
From SEC Form 4 filings by MTRI's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MTRI is in one of them and how their past MTRI trades turned out.
InMed Pharmaceuticals is a drug development company based in Vancouver, Canada. It develops small molecule drug candidates that act on the CB1 and CB2 receptors of the endocannabinoid system, which is found throughout the body. Its pipeline targets Alzheimer's disease, dry macular degeneration (AMD) and epidermolysis bullosa, a skin condition. Most of its programs are at the preclinical stage, while its cannabinol cream has completed a Phase 2 trial in epidermolysis bullosa.